mones (SCH), who have symptoms of hypothyroidism, dyslipidemia or diabetes mellitus are candidates for levothyroxine (L-T 4 ) therapy [1, 2] . Even if the clinical history does not reveal a cause of thyroid dysfunction (history of thyroidectomy, neck radiotherapy, 131 I treatment for hyperthyroidism, antithyroid drugs, amiodarone, lithium, α-interferon) and there is no goiter, measurement of antithyroperoxidase antibodies (TPOAb) and ultrasonography (US) are not necessary for diagnosis or for the decision to treat [1, 2, 4] . In contrast, according to the definition of Wiersinga [5] , if the clinical history is negative and there is no goiter, measurement of TPOAb and occasional US would be obligatory. Moreover, if these methods do not disclose thyroid disease, the diagnosis of SCH and the consequent indication of treatment would be jeopardized. Therefore, the current definition [1, 2] and the new definition [5] clash when no thyroid disease or other apparent cause of TSH elevation is found. Individuals with TSH ≤ 10 mIU/l deserve greater attention because they account for approximately 90% of SCH cases [2] as well as most cases of hyperthyrotropinemia of nonthyroid cause, and due to the controversy regarding the treatment of patients with this degree of TSH elevation [1, 2, 5] .
The approach to subclinical hypothyroidism (SCH) in adults has been extensively discussed in the European Thyroid Journal [1] [2] [3] [4] [5] . SCH is traditionally defined by elevation of the serum TSH, with circulating thyroid hormone concentrations within the reference range [1, 2, 5] . In a recent editorial, Professor Wiersinga proposed to add the presence of thyroid disease for the diagnosis of SCH [5] . This new definition prevents the erroneous treatment of individuals with hyperthyrotropinemia unrelated to thyroid insufficiency [5] . Some conditions that can elevate serum TSH can be recognized easily (untreated adrenal insufficiency, chronic renal failure, antidopaminergic drugs, recovery from severe acute disease). Additionally, when the normal range obtained for adults is used, a discrete elevation of TSH can be seen in older adults (>70 years) [2, 5] . Morbidly obese individuals may also exhibit discretely elevated TSH [2, 6] . Elevated TSH can also occur in individuals with a mutation in the TSH receptor that causes reduced function [2] , or because of the predominance of TSH isoforms with low biological activity [2] , or because of analytical interferences.
According to current recommendations, individuals younger than 70 years with persistently elevated serum TSH with normal concentrations of thyroid hor-In order to contribute additional information about this group, we report here our experience regarding the frequency and long-term evolution of this condition. The population studied was from the metropolitan region of Belo Horizonte (Brazil), an area where iodine intake is adequate. Between March 2003 and April 2010, 618 women not treated with L-T 4 and with TSH >4.5 and ≤ 10 mIU/l were initially selected [7, 8] . Women were excluded from this group if they were pregnant or attempting to become pregnant in the short term. Women with a nonthyroid cause of TSH elevation (untreated adrenal insufficiency, chronic renal failure, antidopaminergic drugs, recovery from severe acute disease), women treated with antithyroid drugs, amiodarone, lithium and α-interferon, and women with a history of thyroidectomy, neck radiotherapy and 131 I treatment for hyperthyroidism were also excluded. Thus, 152 patients were excluded. The remaining patients (n = 466) were reevaluated by measurement of TSH and free T 4 after 6-12 weeks. Of these, 374 patients had persistently elevated TSH ranging from 4.5 to 10 mIU/l and normal free T 4 ; 304 of them had circulating TPOAb or exhibited US alterations suggestive of thyroiditis/goiter. Seventy women had negative TPOAb and US revealed a eutopic thy- 274 roid, usual echogenicity and a volume ≤ 15 ml [9] (group of interest). All of these women were ≤ 70 years and had a BMI ≤ 35. TSH and free T 4 were then measured at intervals of 6 months in these women. L-T 4 therapy was initiated if serum TSH increased to >10 mIU/l accompanied by reduced free T 4 , or if there were two TSH values >10 mIU/l within an interval of 8 weeks [7, 8] . Three patients were lost early. One woman wished to become pregnant during follow-up and L-T 4 therapy was thus initiated. The study was approved by the Research Ethics Committee of our institution.
Serum samples were obtained in the morning (at about 8 a.m.) after a 10-hour fast. TSH, TPOAb and free T 4 were measured with a chemiluminescent assay (Immulite 2000; Diagnostic Products Corp., Los Angeles, Calif., USA), with reference values of 0.4-4 mIU/l, up to 35 kIU/l and 10.3-23 pmol/l, respectively. US was performed with a multifrequency (12-14 MHz) linear transducer and the examiner was blind to the thyroid status of the patient.
After a follow-up of 5-12 years (median: 8.8), only 6 women were treated with L-T 4 (see criterion above). Thirty-six women showed spontaneous normalization of TSH (sustained until the last assessment).
Persistently elevated TSH (<8 mIU/l) was observed in 18 women and TSH oscillated between normal and discretely elevated concentrations ( ≤ 7 mIU/l) in 6. At the end of the fourth year of follow-up, 33 women continued to have elevated TSH. From this time on, during a follow-up of 1-8 years, only 1 patient (3%) required L-T 4 therapy. In the case of the 24 women with elevated TSH (constant or intermittent) in the last assessment, TPOAb and US were repeated and remained negative in all of them.
Even after confirmation of the result and exclusion of known nonthyroid causes of TSH elevation, clinical history, TPOAb measurement or US did not disclose thyroid disease in approximately 20% of women with elevated TSH ≤ 10 mIU/l and normal free T 4 . This frequency was obtained in a group aged ≤ 70 years [2, 5] and with a BMI <35 [6] . This finding suggests that the definition proposed by Wiersinga [5] could lead to a revision of the diagnosis in a significant portion of patients diagnosed with SCH [1, 2] . In the long term (minimum follow-up of 5 years), progression of hypothyroidism was uncommon in these cases (9%), while spontaneous and sustained normalization of TSH was frequent (54%). Furthermore, TPOAb and US continued not to show thyroid disease.
These data support the hypothesis that, at least in most cases, initial elevation of TSH (when SCH was diagnosed [1, 2] ) did not represent the early phase of thyroid insufficiency. We therefore agree that much care should be taken when diagnosing SCH in the absence of apparent thyroid disease and even more when L-T 4 therapy is considered. This therapy is included in the guidelines [2] and is often recommended by clinicians even when TSH is <10 mIU/l and in the absence of circulating TPOAb or goiter.
Finally, the recommendation of annual follow-up after the second year in individuals with persistently elevated TSH [2] may not apply to all cases. Specifically in cases without apparent thyroid disease, if TSH does not progress after 4 years of follow-up, the chance that this occurs seems low and laboratory reassessment could be reserved in the case of appearance/worsening of signs or symptoms or pregnancy planning. In the absence of these conditions, reassessment could be performed less frequently, for example at intervals of 3-5 years.
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